Opportunities for novel therapeutic agents acting at chemokine receptors.

Abstract:

:Chemokines are proinflammatory mediators that primarily control leukocyte migration into selected tissues and upregulation of adhesion receptors. They also have a role in pathological conditions that require neovascularization and are implicated in the suppression of viral replication. By interaction with their respective G-protein-coupled receptor, chemokines have a profound influence over the selective recruitment of specific cell types in acute inflammatory disease and, hence, inhibition of their action should be of therapeutic benefit. Only now are small molecule inhibitors becoming available to validate this speculation. In this review, without seeking to be comprehensive, the authors provide an introduction to chemokines, their receptors and their role in certain disease processes. Also, recent disclosures claiming novel nonpeptide ligands for chemokine receptors are summarized.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Saunders J,Tarby CM

doi

10.1016/s1359-6446(98)01280-x

subject

Has Abstract

pub_date

1999-02-01 00:00:00

pages

80-92

issue

2

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(98)01280-X

journal_volume

4

pub_type

杂志文章
  • Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?

    abstract::The occurrence of drug resistance in oncology accounts for treatment failure and relapse of diverse tumor types. Cancers contain cells at various stages of differentiation together with a limited number of 'cancer-initiating cells' able to self-renew and divide asymmetrically, driving tumorigenesis. Cancer-initiating ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.02.005

    authors: Alama A,Orengo AM,Ferrini S,Gangemi R

    更新日期:2012-05-01 00:00:00

  • Genomics and transcriptomics in drug discovery.

    abstract::The popularization of genomic high-throughput technologies is causing a revolution in biomedical research and, particularly, is transforming the field of drug discovery. Systems biology offers a framework to understand the extensive human genetic heterogeneity revealed by genomic sequencing in the context of the netwo...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.06.003

    authors: Dopazo J

    更新日期:2014-02-01 00:00:00

  • Cancer therapy via modulation of micro RNA levels: a promising future.

    abstract::Micro RNAs (miRNAs) are a class of naturally occurring ∼ 22 nt long non-coding small RNA molecules that regulate the expression of a wide range of genes involved in development, growth, proliferation and apoptosis. miRNAs are evolutionarily conserved from plants to animals, and they regulate and fine-tune a diverse ar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.07.003

    authors: Kota SK,Balasubramanian S

    更新日期:2010-09-01 00:00:00

  • Current and future trends in the application of HPLC-MS to metabolite-identification studies.

    abstract::Metabolic determinations are an integral part of every drug-discovery and drug-development program. Recent emphasis has been to increase sample throughput while, at the same time, increase information content within assays. To this end, screening for potential drug-drug interactions, overall metabolic stability and me...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.01.007

    authors: Castro-Perez JM

    更新日期:2007-03-01 00:00:00

  • Applying genetics in inflammatory disease drug discovery.

    abstract::Recent groundbreaking work in genetics has identified thousands of small-effect genetic variants throughout the genome that are associated with almost all major diseases. These genome-wide association studies (GWAS) are often proposed as a source of future medical breakthroughs. However, with several notable exception...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2015.05.012

    authors: Folkersen L,Biswas S,Frederiksen KS,Keller P,Fox B,Fleckner J

    更新日期:2015-10-01 00:00:00

  • Rational drug discovery: what can we learn from regulatory networks?

    abstract::To enable the list of genes and proteins contained within genomic databases to be useful for drug discovery, we need to understand how the genome maps into the phenome. An essential, but not explicitly listed ingredient of the genome is the regulatory interactions between genes and proteins that form a genome-wide net...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02463-7

    authors: Huang S

    更新日期:2002-10-15 00:00:00

  • Excessive intimal hyperplasia in human coronary arteries before intimal lipid depositions is the initiation of coronary atherosclerosis and constitutes a therapeutic target.

    abstract::The consensus hypothesis on coronary atherosclerosis suggests high LDL-C levels as the major cause and pursues it as the therapeutic target, explicitly assuming: (i) tunica intima of human coronaries consists of only one cell layer - endothelium, situated on a thin layer of scarcely cellular matrix; and (ii) subendoth...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.05.017

    authors: Subbotin VM

    更新日期:2016-10-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01831-1

    authors: Langston S,Barlocco D

    更新日期:2001-07-01 00:00:00

  • Driving external chemistry optimization via operations management principles.

    abstract::Confronted with the need to significantly raise the productivity of remotely located chemistry CROs Pfizer embraced a commitment to continuous improvement which leveraged the tools from both Lean Six Sigma and queue management theory to deliver positive measurable outcomes. During 2012 cycle times were reduced by 48% ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.07.017

    authors: Bi FC,Frost HN,Ling X,Perry DA,Sakata SK,Bailey S,Fobian YM,Sloan L,Wood A

    更新日期:2014-03-01 00:00:00

  • Natural products in drug discovery.

    abstract::Natural products have been the single most productive source of leads for the development of drugs. Over a 100 new products are in clinical development, particularly as anti-cancer agents and anti-infectives. Application of molecular biological techniques is increasing the availability of novel compounds that can be c...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.07.004

    authors: Harvey AL

    更新日期:2008-10-01 00:00:00

  • Novel antitumour molecules.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01619-6

    authors: Westwell A

    更新日期:2001-02-01 00:00:00

  • The TNF superfamily is on the TRAIL to BlyS.

    abstract::Highlights of the 9th (Biennial) International Congress on TNF-Related Cytokines (30 October-2 November 2002; The Manchester Grand Hyatt, San Diego, CA, USA. ...

    journal_title:Drug discovery today

    pub_type:

    doi:10.1016/s1359-6446(02)02592-8

    authors: Steed PM,Hubert RS

    更新日期:2003-02-01 00:00:00

  • Poetry and verse: an ideal medium for scientific communication?

    abstract::'Many professional scientists over the years have expressed their thoughts and ideas in poetry.' ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01556-7

    authors: Rowe RC

    更新日期:2000-10-01 00:00:00

  • Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases.

    abstract::Fatty acid amide hydrolase (FAAH) is responsible for the hydrolysis of several important endogenous fatty acid amides (FAAs), including anandamide, oleoylethanolamide and palmitoylethanolamide. Because specific FAAs interact with cannabinoid and vanilloid receptors, they are often referred to as 'endocannabinoids' or ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.08.002

    authors: Pillarisetti S,Alexander CW,Khanna I

    更新日期:2009-12-01 00:00:00

  • Improved mouse models and advanced genetic and genomic technologies for the study of neutrophils.

    abstract::Mice have been excellent surrogates for studying neutrophil biology and, furthermore, murine models of human disease have provided fundamental insights into the roles of human neutrophils in innate immunity. The emergence of novel humanized mice and high-diversity mouse populations offers the research community innova...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.03.018

    authors: Hosur V,Skelly DA,Francis C,Low BE,Kohar V,Burzenski LM,Amiji MM,Shultz LD,Wiles MV

    更新日期:2020-06-01 00:00:00

  • Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness.

    abstract::Identification and validation of viable targets is an important first step in drug discovery and new methods, and integrated approaches are continuously explored to improve the discovery rate and exploration of new drug targets. An in silico machine learning method, support vector machines, has been explored as a new ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.02.015

    authors: Han LY,Zheng CJ,Xie B,Jia J,Ma XH,Zhu F,Lin HH,Chen X,Chen YZ

    更新日期:2007-04-01 00:00:00

  • Immunotherapies in cutaneous pathologies: an overview.

    abstract::Skin is a vital protective organ, the main role of which is to provide a physical barrier and to prevent the entry of pathogens. Various pathologies, such as atopic dermatitis (AD), psoriasis (PSO), or skin cancers, can affect the skin, and all show a high and increasing prevalence. Many antibodies are currently used ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.10.023

    authors: Baylet A,Laclaverie M,Marchand L,Bordes S,Closs-Gonthier B,Delpy L

    更新日期:2021-01-01 00:00:00

  • Dopaminergic agents for the treatment of cocaine abuse.

    abstract::Cocaine is a major drug of abuse whose devastating effects have captured the attention of health officials and policy makers. Based upon the alarming health and crime-related costs associated with the use of this powerful reinforcing drug, immediate therapies are needed for the treatment of cocaine addiction. In this ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(99)01332-x

    authors: Smith MP,Hoepping A,Johnson KM,Trzcinska M,Kozikowski AP

    更新日期:1999-07-01 00:00:00

  • Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.

    abstract::Drug therapy for the treatment of tumors is often limited by a narrow therapeutic index. One approach that overcomes this limitation is the active targeting of tumors with particulate drug carriers. The derivatization of particulate drug carriers with a ligand leads to the selective targeting of the particulate to sel...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(03)02988-X

    authors: Marcucci F,Lefoulon F

    更新日期:2004-03-01 00:00:00

  • 3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR.

    abstract::The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters. 3D structures for the ligand-binding domain (LBD) of these receptors are abundantl...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.01.001

    authors: Wu B,Li S,Dong D

    更新日期:2013-06-01 00:00:00

  • Medicinal chemistry matters - a call for discipline in our discipline.

    abstract::Medicinal chemistry makes a vital contribution to small molecule drug discovery, and the quality of it contributes directly to research effectiveness as well as to downstream costs, speed and survival in development. In recent years, the discipline of medicinal chemistry has evolved and witnessed many noteworthy contr...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2012.01.010

    authors: Johnstone C

    更新日期:2012-06-01 00:00:00

  • Target 2035: probing the human proteome.

    abstract::Biomedical scientists tend to focus on only a small fraction of the proteins encoded by the human genome despite overwhelming genetic evidence that many understudied proteins are important for human disease. One of the best ways to interrogate the function of a protein and to determine its relevance as a drug target i...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2019.06.020

    authors: Carter AJ,Kraemer O,Zwick M,Mueller-Fahrnow A,Arrowsmith CH,Edwards AM

    更新日期:2019-11-01 00:00:00

  • The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

    abstract::Lack of predictability of clinical efficacy and safety is an important problem facing pharmaceutical research today. Translational PK-PD has the ability to integrate data generated from diverse test platforms during discovery and development in a mechanistic framework. Therefore, successful implementation of translati...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.10.002

    authors: Agoram BM,Martin SW,van der Graaf PH

    更新日期:2007-12-01 00:00:00

  • Advanced glycation end products in diabetes, cancer and phytochemical therapy.

    abstract::The irreversible glycation and oxidation of proteins and lipids produces advanced glycation end products (AGEs). These modified AGEs are triggered to bind the receptor for AGE (RAGE), thereby activating its downstream signaling pathways, such as nuclear factor (NF)-κB and phosphoinositide 3-kinase (PI3K)/Akt, ultimate...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.07.003

    authors: Dariya B,Nagaraju GP

    更新日期:2020-09-01 00:00:00

  • The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics.

    abstract::The stratified medicine companion diagnostic (CDx) cut-off decision integrates scientific, clinical, ethical, and commercial considerations, and determines its value to developers, providers, payers, and patients. Competition already sharpens these issues in oncology, and might soon do the same for emerging stratified...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.10.017

    authors: Trusheim MR,Berndt ER

    更新日期:2015-12-01 00:00:00

  • An overview of statin-associated proteinuria.

    abstract::Statins are an established therapeutic modality for the treatment of hypercholesterolemia. Although they generally exhibit a good efficacy and tolerability profile, their reputation has been tarnished as a result of reports of myotoxicity and, more recently, observations of proteinuria. The increased incidence of prot...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.03.017

    authors: Tiwari A

    更新日期:2006-05-01 00:00:00

  • Functionalizing bioinks for 3D bioprinting applications.

    abstract::3D bioprinting has emerged as the intersection between chemistry, biology and technology. Through its integration of cells, biocompatible materials and robotic-controlled dispensing systems, the process enables the production of structures that are biomimetic and functional, thus revolutionizing the concept of tissue ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.09.012

    authors: Parak A,Pradeep P,du Toit LC,Kumar P,Choonara YE,Pillay V

    更新日期:2019-01-01 00:00:00

  • Sharing lessons learnt across European cardiovascular research consortia.

    abstract::Research consortia in Europe often compete with each other for skills, human and technical resources and, eventually, recognition of the scientific impact of their work. In response to the same EU Horizon2020 call, we received funding for our research project proposals to identify and validate novel drug targets for c...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.01.009

    authors: de Jong L,Bobeldijk-Pastorova I,Erdmann J,Bijker-Schreurs M,Schunkert H,Kuivenhoven JA,van Gool AJ

    更新日期:2020-04-01 00:00:00

  • Strategic groups in the biopharmaceutical industry: implications for performance.

    abstract::The biopharmaceutical industry is characterized by intense competition, high uncertainty, and strong dependence on scientific knowledge. We show that in order to succeed in this industry, firms need to be positioned along three strategic dimensions: the level of inter-firm R&D partnering, the level of diversification,...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2009.04.004

    authors: Erden Z,von Krogh G,Nytorp C,Hultberg M

    更新日期:2009-08-01 00:00:00

  • Nanovehicles for co-delivery of anticancer agents.

    abstract::Effective cancer treatment remains a significant challenge in human healthcare. Although many different types of cancer therapy have been tested, scientists have now concluded that combinations of drugs, or drugs plus gene therapy, can target multiple pathways to fight cancer. Nanovehicles can increase drug uptake ins...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.06.027

    authors: Zeinali M,Abbaspour-Ravasjani S,Ghorbani M,Babazadeh A,Soltanfam T,Santos AC,Hamishehkar H,Hamblin MR

    更新日期:2020-08-01 00:00:00